Dr. Ruichao Li 李瑞超
Chief Physician, Associate Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, comprehensive treatment, and precision radiotherapy for lung, esophageal, gastric, and geriatric cancers. Research interest in palliative care.
Dr. Li holds a medical doctorate from Tongji Medical College, Huazhong University of Science and Technology (2000). With over ten years of clinical and research experience in oncology, Dr. Li conducted research on lung cancer chemoprevention at the Medical College of Wisconsin in the United States. Dr. Li has published more than ten papers and participates in national and provincial research projects.
Professional roles
- Member, Difficult Tumor Professional Committee, China Medicine Education Association
Name order: in Chinese the family name comes first (Li Ruichao). Papers usually list the name as Ruichao Li or Li R.
Selected publications
19 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): Thymosin α1 combined with immune checkpoint inhibitors: synergistic remodeling of the tumor immune microenvironment to enhance clinical efficacy and safety. PubMed 42292432
- Am J Case Rep, 2025 (senior author): Neurological and Cardiac Adverse Events in Cervical Cancer Treatment: A Case of Postoperative Sintilimab-Induced Encephalitis and Myocarditis. PubMed 40415286
- Genomics, 2023 (senior author): Long intergenic non-protein coding RNA 00858 participates in the occurrence and development of esophageal squamous cell carcinoma through the activation of the FTO-m6A-MYC axis by recruiting ZNF184. PubMed 36868327
- Curr Mol Pharmacol, 2023 (senior author): BBOX1-AS1 Activates Hedgehog Signaling Pathway to Facilitate the Proliferation and Stemness of Esophageal Squamous Cell Carcinoma Cells via miR-506-5p/EIF5A/PTCH1 Axis. PubMed 36717994
- Am J Transl Res, 2022 (first author): Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value. PubMed 36247295
- Onco Targets Ther, 2019 (senior author): microRNA-605 inhibits the oncogenicity of non-small-cell lung cancer by directly targeting Forkhead Box P1. PubMed 31190877
- Int J Biol Markers, 2014 (first author): The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib. PubMed 24425324
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion